LRP5 and head and neck cancer: We identified LRP5-UBE3C (v1) fusion in 4% (6/151) and UBE3C-LRP5 (v2) fusion in 2.6% of (4/151) head and neck cancer patients (Supplementary Figs. S8a, b, S11a, b).